← brief for 2026-08-10 · Slowing decline

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

Key takeaways

A trial is opening to see if empagliflozin, a diabetes and kidney drug, helps children and teens aged 2 to 17 with chronic kidney disease. Children will be randomly given the drug or a placebo. It also checks how safe the drug is and how a child's body handles it. There are no results yet.

Who did this work

Run by Boehringer Ingelheim.
Sites: University of Alabama at Birmingham · Phoenix Children's Hospital · University of California Los Angeles · Stanford University School of Medicine · University of California Davis · University of California San Francisco

Source

Trial registration · ClinicalTrials.gov — CKD recruiting · 2026-08-07
https://clinicaltrials.gov/study/NCT07107945